ZoBio and Domainex partner to support FORMA Therapeutics’ drug
15 December 2014
Dutch company ZoBio and Cambridge-based Domainex Ltd have
announced a collaboration with US company FORMA Therapeutics to
provide NMR-based structural biology services for a substantial
panel of FORMA drug targets.
The goal of the collaboration is to use ZoBio’s expertise in
protein nuclear magnetic resonance (NMR) to elucidate the molecular
basis for compound-target interaction, to complement ongoing X-ray
crystallography approaches. NMR is currently the only alternative to
crystallography capable of elucidating atomic resolution, 3D
structural information. Under the agreement, ZoBio will design and
express protein variants suitable for structural studies, to support
FORMA’s oncology drug discovery research.
In addition, Domainex will apply its Combinatorial Domain Hunting
technology to generate suitable protein variants for a selection of
particularly challenging targets, not previously amenable to
structural studies. Successful targets from the joint ZoBio/Domainex
effort will be used for subsequent NMR structural biology studies.